» Articles » PMID: 28990810

CNS Metastasis Secondary to Malignant-mixed Müllerian Tumor: Case Report and Review of Therapeutics

Overview
Journal CNS Oncol
Specialty Oncology
Date 2017 Oct 10
PMID 28990810
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

This paper reviews CNS involvement secondary to malignant-mixed Müllerian tumor or uterine carcinosarcoma, a rare aggressive biphasic Müllerian tumor. We report a cerebellar metastasis with epithelial and mesenchymal components, demonstrating heterologous rhabdomyogenic and chondroblastic differentiation. The patient had undergone total abdominal hysterectomy and bilateral salpingo-oophorectomy for palliation of symptomatic chemotherapy-resistant node-positive disease. CNS involvement is rare, and prognostically poor, and suggestively poorer in predominantly sarcomatous metastases. Multimodal therapy is indicated; in solitary metastases, surgical resection or stereotactic radiosurgery is included, followed by whole brain radiotherapy. In unresectable brain metastases, stereotactic radiosurgery and whole brain radiotherapy warrant consideration in up to 2-3 metastases. In multiple metastases, palliative steroid therapy or cranial irradiation may be considered. Combination or platinum-based chemotherapy (i.e., ifosfamide-paclitaxel or carboplatin-paclitaxel) is indicated in all stages, with a role in both disease cure and control-directed management. Targeted therapeutics have thus far not demonstrated significant clinical efficacy.

Citing Articles

Brain Metastasis in Endometrial Cancer: A Systematic Review.

Sambataro D, Gebbia V, Bonasera A, Quattrocchi A, Caputo G, Vinci E Cancers (Basel). 2025; 17(3).

PMID: 39941769 PMC: 11816136. DOI: 10.3390/cancers17030402.


A case report of comprehensive treatment for primary intraspinal carcinosarcoma.

Yan C, Zhang C, Wei J, Liang H, Qu S Front Oncol. 2025; 14():1479193.

PMID: 39839799 PMC: 11747408. DOI: 10.3389/fonc.2024.1479193.


Spinal intramedullary uterine carcinosarcoma metastasis.

Solis W, Youssef A, Shaw R, Li Y BMJ Case Rep. 2024; 17(2).

PMID: 38417940 PMC: 10900381. DOI: 10.1136/bcr-2023-259268.


Magnetic resonance imaging for the diagnosis of malignant mixed Mullerian tumor of ovary: Two case reports.

Jin X, Zhu P, Fan S, Dai J Medicine (Baltimore). 2023; 102(50):e36569.

PMID: 38115369 PMC: 10727683. DOI: 10.1097/MD.0000000000036569.


Uterine Carcinosarcoma: A Case Report and Literature Review.

Kord A, Rabiee B, Elbaz Younes I, Xie K Case Rep Obstet Gynecol. 2020; 2020:8816348.

PMID: 32884852 PMC: 7455848. DOI: 10.1155/2020/8816348.


References
1.
Lam K, Khoo U, Cheung A . Collision of endometrioid carcinoma and stromal sarcoma of the uterus: a report of two cases. Int J Gynecol Pathol. 1999; 18(1):77-81. DOI: 10.1097/00004347-199901000-00012. View

2.
Hacker N, Rao A . Surgical management of lung, liver and brain metastases from gynecological cancers: a literature review. Gynecol Oncol Res Pract. 2016; 3:7. PMC: 4912748. DOI: 10.1186/s40661-016-0028-3. View

3.
Inno A, Di Noia V, DArgento E, Modena A, Gori S . State of the art of chemotherapy for the treatment of central nervous system metastases from non-small cell lung cancer. Transl Lung Cancer Res. 2017; 5(6):599-609. PMC: 5233886. DOI: 10.21037/tlcr.2016.11.01. View

4.
Homesley H, Filiaci V, Markman M, Bitterman P, Eaton L, Kilgore L . Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2007; 25(5):526-31. DOI: 10.1200/JCO.2006.06.4907. View

5.
Nimeiri H, Oza A, Morgan R, Huo D, Elit L, Knost J . A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol. 2010; 117(1):37-40. PMC: 2842466. DOI: 10.1016/j.ygyno.2010.01.013. View